Home > Insider Trading > Filing (0001181431-10-041137)

Filing Details

Accession Number:: 0001181431-10-041137
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-08-10 13:00:00
Reporting Period:: 2010-08-06

Filing Date:: 2010-08-10
Accepted Time:: 2010-08-10 14:12:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356857	Trius Therapeutics Inc	TSRX	Pharmaceutical Preparations (2834)	201320630

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1456585	Versant Side Fund Iii, L.p.	C/O Versant Ventures 3000 Sand Hill Road, Bldg. 4, Ste. 210 Menlo Park CA 94025		No	No	Yes	No
1456586	Versant Venture Capital Iii, L.p.	3000 Sand Hill Road Bldg. 4, Ste. 210 Menlo Park CA 94025		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-08-06	1,576,814	$0.00	1,576,814	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2010-08-06	744,496	$4.38	2,321,310	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2010-08-06	914,529	$5.00	3,235,839	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2010-08-06	9,090,910	$0.00	9,090,910	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-08-06	4,469,697	$0.00	4,469,697	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering, each 8.6 shares of the Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of Common Stock, and had no expiration date.
The shares are held as follows: 1,567,556 shares held by Versant Venture Capital III, L.P. and 9,258 shares held by Versant Side Fund III, L.P.
The Common Stock was acquired upon conversion of a Secured Convertible Promissory Note exempt from the definition of a derivative security and whose conversion ratio did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering. The shares are held as follows: 740,126 shares held by Versant Venture Capital III, L.P. and 4,370 shares held by Versant Side Fund III, L.P.
The shares were purchased in the Issuer's initial public offering and are held as follows: 909,160 shares held by Versant Venture Capital III, L.P. and 5,369 shares held by Versant Side Fund III, L.P.
The shares are held as follows: 9,037,534 shares held by Versant Venture Capital III, L.P. and 53,376 shares held by Versant Side Fund III, L.P.
) The shares are held as follows: 4,443,454 shares held by Versant Venture Capital III, L.P. and 26,243 shares held by Versant Side Fund III, L.P.
In their capacity as managing members of Versant Ventures III, LLC, which is the general partner of each of the Versant Funds, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden and Barbara N. Lubash share voting and investment authority over the shares held by the Versant Funds and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden and Barbara N. Lubash disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.